- Home
- ARCL vs AARD Comparison
ARCL vs AARD Comparison
Compare ARCL & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$4.99
Company Overview
Basic Information| Metric | ARCL | AARD |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.4M | 165.8M |
| IPO Year | 2025 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ARCL | AARD |
|---|---|---|
| Price | $10.01 | $4.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 14.6K | ★ 122.1K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $3.35 |
| 52 Week High | $10.01 | $17.94 |
Technical Indicators
Market Signals| Indicator | ARCL | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 68.98 | 37.62 |
| Support Level | $9.88 | $3.38 |
| Resistance Level | N/A | $6.01 |
| Average True Range (ATR) | 0.02 | 0.76 |
| MACD | 0.00 | -0.19 |
| Stochastic Oscillator | 100.00 | 2.73 |
Price Performance
Historical Comparison ARCL
AARD
About ARCL ARC Group Acquisition I Corp Class A Ordinary Shares
ARC Group Acquisition I Corp is a blank check company.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.